Professor Hugh Durrant-Whyte: GMP Lite is about what we can do in biomaufacturing in general – how we can use life to create new products in different kinds of ways, whether it’s through mammalian cell cultures or through many other algae cells and so on. I think the other dimension that’s really important about GMP Lite is the engagement between academia and industry – that is, it’s a facility which is not just about university research and university training; it’s about engaging with industry and engaging in training industry and using that facility to prototype, to explore, to start to develop new products that industry are genuinely engaged in.
Dr Uma Sinha Datta: I think GMP in Australia is the first of its kind. It is equipped with single-use manufacturing tools, which is kind of like a green way of manufacturing going forward, using much less water, much less chemicals, having a much lesser carbon footprint compared to the traditional stainless-steel manufacturing system.
Dr Stuart Newman: So in addition to offering education and training to the biologics workforce of the future, the GMP Lite facility also is potentially a sandbox for development of processes. The value of a sandbox approach is that processes for production can be trialled and refined before proceeding to a risky and expensive production run.
Dr Noelle Sunstrom: A GMP facility actually gives us focused R&D in this area and how we might be able to scale up our manufacturing processes here in Australia and then transfer them to our larger biologic manufacturing facilities.
Dr Brad Walsh: I think we have been a little bit behind the rest of the world in terms of competitiveness. Clinical trials are really that big next step, and good clinical trials. Getting that actual last piece of the puzzle that says, ‘yes, we can now help you to make your product at the quality you need locally’ is a big step forward.
Dr Evan Shave: So, the biotech space in Australia in 10 years’ time will hopefully be vibrant and will have expanded a lot from where it is today, hopefully is broader in terms of the type of drugs that are being made and developed and hopefully commercialised and that there’s more of an end-to-end business in Australia for biotech.
John Ince: The opportunity for Australia and the impact this can have on Australia and the competitiveness in really the growth industry of the world, which is Southeast Asia, is here, and there really is an opportunity to capture that enormous growth across biologics manufacturing and the next generation of human therapeutic manufacturing. So, really, this is the time, this is now, and I think Australia, and New South Wales in particular, in investing in this, is at the cusp to be able to create our own destiny.
For bookings or more information
Edwin Huang, Biologics Innovation Facility Manager or Andrew Groth, Science faculty Business Development Manager at email@example.com
New funding for biologics facility will keep research local
Funding boost from NSW Government for UTS Biologics Innovation Facility announced.
Meet the team